Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials.

Abstract

Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day). Nonathymulin 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56% v 17% in the placebo group) (p less than 0.02) and by four objective parameters. This effect was accompanied with minimal adverse effects and was not associated with clear changes in immunological parameters. A significant correlation was observed, however, in clinical response to nonathymulin, and T cell subset imbalance was assessed using monoclonal anti-T cell antibodies and a functional suppressor T cell assay.

• Authors: B Amor, M Dougados, C Mery, M Dardenne, J F Bach
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 46 Issue 7 Pg. 549-54 (Jul 1987) ISSN: 0003-4967 [Print] England
• PMID: 3310925 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Thymus Hormones
• Thymic Factor, Circulating

Topics

• Arthritis, Rheumatoid (drug therapy, immunology)
• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Humans
• Male
• Random Allocation
• Thymic Factor, Circulating (administration & dosage, adverse effects, therapeutic use)
• Thymus Hormones (therapeutic use)